A new study led by the University of Bristol has shown a common eye condition, glaucoma, could be successfully treated with a single injection using gene therapy, which would improve treatment options, effectiveness and quality of life for many patients.
Glaucoma affects over 64 million people worldwide and is a leading cause of irreversible blindness. It is usually caused by fluid building up in the front part of the eye, which increases pressure inside the eye and progressively damages the nerves responsible for sight. Current treatments include either eye drops, laser or surgery, all of which have limitations and disadvantages.
The research team led by academics at the Bristol Medical School: Translational Health Sciences tested a new approach that could provide additional treatment options and benefits. Their findings are published in the journal Molecular Therapy.
The researchers designed a gene therapy and demonstrated proof of concept using experimental mouse models of glaucoma and human donor tissue.
The treatment targeted part of the eye called the ciliary body, which produces the fluid that maintains pressure within the eye. Using the latest gene editing technology called CRISPR, a gene called Aquaporin 1 in the ciliary body was inactivated leading to reduced eye pressure.
Dr Colin Chu, Visiting Senior Research Fellow in the Bristol Medical School: Translational Health Sciences and corresponding author, said: “Currently there is no cure for glaucoma, which can lead to loss of vision if the disease is not diagnosed and treated early.
“We hope to advance towards clinical trials for this new treatment in the near future. If it’s successful it could allow a long-term treatment of glaucoma with a single eye injection, which would improve the quality of life for many patients whilst saving the NHS time and money.”
The academics are currently in discussion with industry partners to support further laboratory work and rapidly progress this new treatment option towards clinical trials.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Glaucoma
- Content creator claims wearing sunglasses can harm your eyes. So, have we been wrong all this while?
“Sunglasses don’t protect your eyes, they actually do the opposite,” he cautions his followers. In the post, he continues to explain the reason behind this bold claim. “Human biology dictates that ...
- Questions About Dog Health? Veterinarians Have The Answer.
Allergies, which can cause skin problems. This article discusses the common health concerns of Chihuahuas, including dental issues, low blood sugar, kneecap dislocation, heart problems, tracheal ...
- Ex-FBI informant charged with lying about Bidens must remain jailed, appeals court rules
A federal appeals court has rejected a bid to release from jail a former FBI informant who is charged with fabricating a multimillion-dollar bribery scheme involving President Joe Biden’s family ...
- Biden plans to drastically change federal rules on marijuana, here's where NC stands
Marijuana is currently federally scheduled in the same class as drugs like heroin and LSD, but sources say that this could change on a federal level. Here's what's happening and what it could mean for ...
- Want Green Eyes? That'll Be $12,000
Keratopigmentation, a procedure to permanently change one’s eye color that has been performed for at least a decade in Europe, is gaining popularity in the United States. Only a handful of clinics in ...
Go deeper with Google Headlines on:
Glaucoma
[google_news title=”” keyword=”glaucoma” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Glaucoma gene therapy
- Ocugen to Present Pioneering Gene Therapy Data at Retinal Innovation Summit
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company, announced that Dr. Benjamin Bakall will present findings from the OCU400 Phase 1/2 clinical trials at the upcoming Retinal Cell ...
- Companies prepare to unveil research at ARVO 2024 conference
More companies have released information on presentations related to their pipelines and new data at the ARVO 2024 conference.
- Invest In A Revolutionary Gene Therapy With CRISPR Therapeutics
CRISPR Therapeutics' Casgevy could generate significant shareholder value if proven to be successful. Learn why I am highly bullish on CRSP stock.
- Nanoscope Therapeutics: Gene Therapy Improves Visual Acuity in Patients with Retinitis Pigmentosa
Gene therapy demonstrated clinically meaningful vision improvement in legally blind individuals. The therapy is capable of restoring vision even in advanced disease stages. The Latest A recent ...
- OSU researchers pioneer technique for delivering gene therapy to specific brain areas
Researchers say the procedure holds promise for a host of genetic neurological disorders, including Parkinson's, Alzheimer's, multiple system atrophy (ASA) and more.
Go deeper with Google Headlines on:
Glaucoma gene therapy
[google_news title=”” keyword=”glaucoma gene therapy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]